Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Phase 2

Completed

Conditions: Postoperative Nausea and Vomiting (PONV)

Interventions: Drug: TAK-951
Drug: Ondansetron
Drug: TAK-951 Placebo
Drug: Ondansetron Placebo

First Posted Date: 2020-09-21

Last Posted Date: 2023-04-21

Lead Sponsor: Takeda

Target Recruit Count: 89

Registration Number: NCT04557189

Locations: 🇺🇸
Stony Brook Medicine - Hospital, Stony Brook, New York, United States
🇺🇸
Phoenix Clinical Research, Tamarac, Florida, United States
🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States

and more 4 locations

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-994
Drug: Placebo

First Posted Date: 2020-09-16

Last Posted Date: 2021-01-19

Lead Sponsor: Takeda

Target Recruit Count: 19

Registration Number: NCT04551079

Locations: 🇺🇸
Clinilabs Drug Development Corporation, New York, New York, United States

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Phase 2

Recruiting

Conditions: Celiac Disease

Interventions: Drug: Placebo
Drug: TAK-101
Dietary Supplement: Gluten

First Posted Date: 2020-08-28

Last Posted Date: 2024-05-06

Lead Sponsor: Takeda

Target Recruit Count: 108

Registration Number: NCT04530123

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
One of a Kind Clinical Research Center LLC, Scottsdale, Arizona, United States
🇺🇸
Precision Research Institute, LLC, Chula Vista, California, United States

and more 79 locations

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: Lanadelumab

First Posted Date: 2020-08-07

Last Posted Date: 2022-03-07

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT04503603

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
Ph+ Mixed Phenotype Acute Leukemia (MPAL)
Philadelphia Chromosome-Like ALL (Ph-like ALL)

Interventions: Drug: Ponatinib
Drug: Ponatinib AAF
Drug: Chemotherapy Agents

First Posted Date: 2020-08-06

Last Posted Date: 2024-08-09

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT04501614

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 61 locations

A Study on Vonoprazan in the Real-world Clinical Practice in China

Completed

Conditions: Esophagitis Peptic

First Posted Date: 2020-08-06

Last Posted Date: 2023-10-25

Lead Sponsor: Takeda

Target Recruit Count: 3000

Registration Number: NCT04501627

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
🇨🇳
Heilongjiang Provincial Hospital (Nanshang), Harbin, Heilongjiang, China
🇨🇳
Wenzhou Central Hospital, Wenzhou, Zhejiang, China

and more 37 locations

A Study of TAK-951 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: TAK-951
Drug: TAK-951 Placebo

First Posted Date: 2020-07-27

Last Posted Date: 2023-03-10

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT04486950

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes

First Posted Date: 2020-07-23

Last Posted Date: 2022-09-30

Lead Sponsor: Takeda

Registration Number: NCT04484363

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Phase 1

Withdrawn

Conditions: Coronavirus Disease

Interventions: Drug: TAK-671
Drug: TAK-671 Placebo

First Posted Date: 2020-07-09

Last Posted Date: 2020-10-08

Lead Sponsor: Takeda

Registration Number: NCT04464460

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: TAK-935
Drug: Placebo

First Posted Date: 2020-07-08

Last Posted Date: 2022-01-11

Lead Sponsor: Takeda

Target Recruit Count: 33

Registration Number: NCT04461483

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy